Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of ($0.05), $0.01 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $10.1 million versus the consensus estimate of $10.5 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.